Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05844527
Other study ID # MRG2023WH
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 20, 2023
Est. completion date October 1, 2024

Study information

Verified date January 2024
Source MedRegen LLC
Contact Ali R Ahmadi, MD PhD
Phone 4437598563
Email info@medregenco.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Surgical excisions are one of the most frequent cutaneous wounds. This study will compare the safety and preliminary efficacy of a novel fixed-dose combination drug MRG-001 in pre-abdominoplasty surgical excisions and scar appearance in subjects undergoing elective abdominoplasty.


Description:

Subjects will undergo surgical excisions in the abdominoplasty area and will be treated with MRG-001 or placebo for 3 weeks. After 6 weeks, the excision area is harvested for analysis and the study is terminated and the abdominoplasty is performed.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date October 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent (which includes the Photographic Release Form and HIPAA) prior to performing any of the Screening Visit procedures. 2. Outpatient, males and females between 18 to 55 years of age, inclusive, at the time of signing the ICF. Female subjects of childbearing potential must have a negative serum pregnancy test at Visit 1a (Study Part A) and 1b (Study Part B) and practice a reliable method of contraception throughout the study. 3. Seeking or scheduled for standard elective abdominoplasty. 4. Willing to undergo directed excisions under local anesthesia and follow-up prior abdominoplasty and to undergo all follow-up visits after abdominoplasty surgery. 5. Nonsmokers (or other nicotine use) as determined by history (no nicotine use over the past 6 months) and by urine cotinine concentration (< 200 ng/mL) at the Screening Visit and prior to admission. 6. Generally, in good health with no clinically significant abnormalities as determined by medical, history, physical examination, 12-lead ECG and clinical laboratory tests. 7. The following applies to female subjects of childbearing potential: • Non-pregnant, non-lactating females of childbearing potential who agree to use medically acceptable forms of birth control (hormonal contraception, abstinence, diaphragm with spermicide, condom with spermicide or intrauterine device) from the Screening Visit until the End-of-study Visit. 8. Body mass index (BMI) between 25 and 35.0 kg/m2, inclusive, at the Screening Visit. 9. Men must be willing to use double-barrier contraception from enrollment until 8 weeks after the last dose of the study drug, if not abstinent. Exclusion Criteria: 1. Participation in any other clinical trial of an experimental treatment or used an investigational drug within the past 30 days. 2. Subject has a clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, hematological or psychiatric disorder(s) as determined by the Principal Investigator or designee. 3. History of diabetes mellitus or an HbA1C greater than 5.7 percent. 4. History of prior abdominal surgery or abdominal liposuction, cryolipolysis, focused ultrasound or other fat reduction procedures in or near the anterior abdomen within 12 months prior to screening. 5. History of poor or delayed wound healing such as prior wound dehiscence, chronic wound or leg ulcer. 6. History of or evidence of a genetic collagen disorder such as Ehlers-Danlos Syndrome. 7. Operating Physician is unable to design an abdominoplasty incision area of at least 25 cm wide by 12 cm tall at the center of the fusiform. 8. The presence of any abnormality of the skin within the area of the proposed abdominoplasty that, in the opinion of the PI, could interfere with the excision process or grading of the resultant surgical scar (e.g., striae gravidarum, striae distensae, excessive nevi, numerous seborrheic keratoses, tattoos, etc.). 9. History of splenectomy or splenomegaly (spleen weighing >750 g). 10. Currently taking immunomodulating drugs (e.g, interferons, interleukin, JAK1/2 inhibitors/corticosteroids). 11. Female subjects who are pregnant or breastfeeding or planning to breastfeed at any time through 90 days after last dose of IP. 12. History of alcohol and/or illicit drug abuse within 2 years of entry. 13. History of hypersensitivity to MRG-001's components (tacrolimus or plerixafor) or hypersensitivity or intolerance to local anesthetics. 14. Any personal, familial, employment or financial situation that could impede the subject's ability to attend all study visits and successfully complete the entire clinical study. 15. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope and possible consequences of the clinical study. 16. Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study. 17. Subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., vulnerable populations, persons in detention, minors and those incapable of giving consent).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MRG-001
MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
Saline
Sterile saline will serve as placebo treatment.

Locations

Country Name City State
United States Northwestern University Feinberg School of Medicine Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
MedRegen LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the preliminary effectiveness of MRG-001 treatment on tensile strength of the scars. The difference in Newton force will be compared between saline and MRG-001. Week -6 to 0
Secondary Evaluate the safety and tolerability of MRG-001 treatment compared to placebo controls. The number of (serious) adverse events will be compared between MRG-001 and placebo Week -6 to 0
Secondary Evaluate the pharmacokinetics of MRG-001 (plerixafor and tacrolimus) in patients with wounds. The following parameters will be assessed: Maximum concentration, trough levels, Minimum concentrations, Clearance and half-life. Week -6 to 0
Secondary Evaluate the pharmacodynamics of wound healing with MRG-001 treatment by measuring the presence of stem cells and immune cells in the peripheral blood and granulation tissue compared to placebo controls. Week -6 to 0
Secondary Assess the time to full re-epithelization of the wounds assessed by digital photography by three independent plastic surgeons. Week -6 to 0
Secondary Assess the scar appearance by the modified POSAS (PI & Patient) at 6 weeks. Week -6 to 0
Secondary Assess the difference in VAS pain scores. Week -6 to 0
Secondary Incidence of wound infection requiring antibiotic therapy within 28 days after excision. Week -6 to 0
Secondary Assess the effect of MRG-001 on the histological presence of stem cells and immunoregulatory cells in the scars. The number of CD133+, CD34+ FOXP3+, Macrophages will be compared between MRG-001 and placebo in the wound area. Week -6 to 0
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Active, not recruiting NCT03649308 - Negative Pressure Wound Therapy Compared to Traditional Care After Skin Grafting N/A
Active, not recruiting NCT03796988 - Autologous Regeneration of Tissue (ART) for Wound Healing N/A
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT05588583 - A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. N/A
Suspended NCT01301118 - Graft Take and Microbiology in Burns N/A
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Completed NCT03938584 - The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients N/A
Not yet recruiting NCT05324514 - Microscopic Skin Tissue Column Grafting Technique Using the Autologous Regeneration of Tissue System N/A
Recruiting NCT05608317 - A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing N/A
Completed NCT04771819 - Safety and Performance of SWIS in Superficial Wounds N/A
Active, not recruiting NCT05263713 - Aesthetic Outcome of Running Subcuticular Suture Versus Running Horizontal Mattress Suture Closure of Linear Wounds on the Trunk and Extremities N/A
Recruiting NCT05741866 - Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs) N/A
Completed NCT01348841 - Wound Interdisciplinary Teams (WIT): A Community- Based Pragmatic Randomized Controlled Trial N/A
Recruiting NCT05217160 - Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers Phase 4
Recruiting NCT03346694 - Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing N/A
Completed NCT03481907 - Topical Collagen Powder for Healing of Acute Full-thickness Wounds N/A
Completed NCT01658163 - Use of 2-octyl-cyanoacrylate Together With a Self-adhering Mesh N/A
Recruiting NCT06178289 - Effectiveness of 3M Cavilon Advanced Skin Protectant in the Treatment of Moisture-associated Skindamage in Nursinghomes N/A
Recruiting NCT05727995 - Efficacy of Prophylactic Negative Pressure Wound Therapy (NPWT) N/A